“…In this work, novel, potential K. pneumoniae antigens with a high predominance in carbapenem-resistant clinical isolates were identified and characterized in silico, using a reverse vaccinology approach. Using several available bioinformatics tools ( Table S1 ) [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , a multiepitope vaccine containing T and B cell epitopes of the antigens was designed and characterized for its antigenic potential. We also assessed the molecular docking between our multiepitope vaccine and TLR-2 and TLR-4, due to their importance in K. pneumoniae infection [2] , [10] , [14] , [18] , [19] .…”